Hematopoietic Stem Cell Transplantation Program

The Hematopoietic Stem Cell Transplantation (HSCT) Program in the Division of Bone Marrow Transplant and Research Immunology has been offering transplants for nearly 30 years. Our transplant doctors have performed more than 1,300 transplants. Fifty percent of all pediatric bone marrow transplants in Los Angeles County are performed by the HSCT Program at Children's Hospital Los Angeles. More than 50 percent of the patients we treat are under five-years-old.

We perform allogeneic transplants, using stem cells from related or unrelated donors, peripheral blood stem cells or cord blood, providing care for patients with advanced-stage and high-risk diseases, including:

Leukemia and lymphoma
Aplastic anemia, Fanconi’s anemia and other marrow failures
Complex inherited diseases of blood cells, such as:
- Severe Combined Immune Deficiency
- Hereditary Lymphohistiocytosis
- Wiskott-Aldrich syndrome
- X-linked Hyper IgM syndrome
- Chronic Granulomatous disease
- Sickle Cell disease
- Thalassemia syndromes
- Hurler’s syndrome
- X-linked adrenoleukodystrophy

Facilities

Our HSCT Program offers a 14-bed nursing unit with HEPA-filtered isolation rooms, specifically suited for the care of pediatric HSCT patients with a high ratio of nurses per patient and two full-time social workers. The rooms feature advanced-laminar airflow that protects patients from airborne germs. In addition, two negative pressure rooms are available for children who have infections that could spread to other patients.

The Day Hospital of the Children's Center for Cancer and Blood Diseases is where outpatient treatments are offered, such as blood transfusions, when patients are ready for discharge from the hospital.

Research Advances

Our team of doctors, nurses and laboratory scientists is renowned for its many innovative research and clinical advances. Our hospital is one of the primary referral centers in the U.S. for children born with severe combined immune deficiency (SCID).

In 1993, Children's Hospital Los Angeles physicians were the first to use gene therapy for newborns with SCID and they continue to remain at the forefront of this emerging area.
Doctors at our hospital have developed innovative, new clinical approach for treating children with SCID, with the goal of restoring all aspects of protective immunity with fewer side-effects than standard transplant approaches.